Technology→ Capabilities→ Availability→ Blog→ About→ Contact→ Request access
Research Use Only (RUO) software · not for diagnostic procedures · EU data residency
Core technology

Genomic interpretation, engineered to be inspected.

One automated chain built on proven, open bioinformatics — extended with interpretation engines designed for auditability rather than opacity.

Widely adopted bioinformatics standardsACMG/AMP · ClinGen SVICPIC · DPWG
The alternative to saying “not evaluable” is not silence. It is asserting normality with no basis.
DESIGN RULE · COVERAGE GOVERNANCE
The product, in view

Ranked findings, with the reasoning attached

This is the screen a geneticist works in after the chain has run: every finding ranked by class, with its zygosity, its flags and the state of its sign-off.

app.innovaregenetics.com
Innovare interpretation workspace listing variants ranked by ACMG class, with zygosity and a sign-off status for each
The interpretation tab. Sample identifiers removed. Automated output, pending professional review and signature.

The class is derived from the criteria, then signed by a person

Each variant carries a ledger of the ACMG criteria applied and of those evaluated but not applied. The geneticist can add phenotypic, family or functional evidence, withdraw an engine criterion when there is evidence against it, write a comment and sign off. Nothing is issued as a research result until a qualified professional has reviewed it.

app.innovaregenetics.com
Variant card showing the ACMG criteria applied, and the curation panel where a geneticist adds evidence and signs
Criteria ledger and curation panel. Sample identifiers removed. Automated output, pending professional review and signature.
The interpretation chain

Six stages, each one inspectable

Innovare runs one continuous pipeline from raw reads to a signed report. Each stage is built on established tools and extended where genomic research needs more than a standard pipeline gives.

Alignment & calling

Quality recorded, not discarded

Industry-standard alignment and calling, with mapping quality and coverage recorded per region, so an ambiguous mapping is reported as unresolved rather than silently dropped.

ACMG engine

A ledger, not a verdict

A Bayesian ACMG interpretation model aligned with ClinGen SVI recommendations, which classifies variants and records every criterion applied — and every one deliberately not applied — as an auditable ledger.

ClinGen SVIBayesian
Pharmacogenomics

CYP2D6, interpreted on its own terms

A specialised locus-specific analysis, so the locus is interpreted on its own terms instead of inheriting a result from a general-purpose variant file.

CPIC · DPWG
Polygenic risk

Ancestry inferred, then calibrated

Scoring against reference panels with explicit ancestry inference, so a percentile is interpretable across Iberian and admixed Latino populations.

275+ traits
Annotation & evidence

Deep-linked to the source

Annotation enriched with public clinical databases and curated gene–disease knowledge bases, deep-linked back to the primary source for every call.

ClinVargnomAD
Visual review

Read level, in the portal

An embedded read-level browser lets a geneticist inspect any variant against the aligned reads before signing, without leaving the review.

read-level
The interpretation workspace

Where the scientist actually works

Once the chain has run, the findings land in an interactive workspace built for the person who has to decide what goes into the report — and for the research group that needs to explore a cohort before anything is reported at all.

Prioritisation

Filter on your own criteria

Configurable filters over the complete result table: search by condition or by variant, and filter through standardised medical ontologies — UMLS, MeSH, Disease Ontology and HPO. Simple and compound sorting, with paginated navigation over tables of any size.

UMLS · MeSHDO · HPO
Curation

A shortlist that survives the session

Row-level selection that persists across pages, filters and re-sorting, with select-all, invert and clear. A shortlist can be built over several passes through the data without losing it, and the counter tells you how many of your selections the current filter is hiding.

persistent selection
Evidence

The source, one click away

Where a valid rsID is present, direct links to dbSNP and SNPedia are generated automatically, so nobody retypes an identifier into a search box. Where no rsID can be extracted, the workspace says so explicitly instead of leaving a blank cell.

dbSNP · SNPedia
Cohorts

Aggregated polygenic view

Aggregate polygenic scores by condition, gene, variant or ontology, either exploratory across the whole dataset or targeted at a selection. Partial and multi-term search included. It answers where the polygenic load actually concentrates, rather than variant by variant.

exploratory & targeted
Overview

Know the dataset before you read it

A statistics panel with record counts, ranges, means and standard deviations for the numeric columns, and the number of distinct conditions present. A fast read of the shape of the data before committing time to it.

summary statistics
Output

Export built for reporting and reuse

Export every row that matches the current filter, or only the ones you selected, choosing the columns. TSV that can be re-imported, formatted XLSX for further analysis, and PDF with orientation, font and layout control for the record.

TSV · XLSX · PDF

Standard inputs, one reference

FASTQ, BAM and VCF from whole-exome sequencing, targeted panels and microarrays, on hg38. Required fields are validated on upload and reported explicitly when something is missing, so a malformed file fails at the door rather than halfway through an analysis.

Named access, defined roles

Every account carries a defined set of permissions, so confidentiality and traceability of genomic and associated research data hold across a team rather than depending on who happened to open the file.

Findings are linked to a continuously updated knowledge base covering more than 40,000 conditions and 4,000 drugs.

Stated limits

Every tab says what it cannot see

Pseudogenes, copy number, repeat expansions and carrier screening are where a short-read pipeline can fail without saying so. Each of these tabs opens with what the method can and cannot conclude.

Phenotype and drug-level guidance, gene by gene

One card per pharmacogene with the inferred phenotype, coverage of the positions assessed and the drug recommendations tied to that phenotype, with their source (CPIC, DPWG, FDA).

app.innovaregenetics.com
Pharmacogenomics tab with one card per gene, showing phenotype, coverage and drug recommendations
Pharmacogenomics tab. Sample identifiers removed. Automated output, pending professional review and signature.

A gain without dosage curation is not benign

The tab opens by stating that any loss or gain requires orthogonal confirmation, and that nothing appearing here excludes an event. Events seen by a single tool are labelled as suspected, not reported.

app.innovaregenetics.com
Copy-number tab opening with a notice that nothing appearing there excludes an event, followed by the events table
Copy number tab. Sample identifiers removed. Automated output, pending professional review and signature.

A normal copy number is not a negative

For genes with a pseudogene, a positive is never reported on short reads alone. The tab says explicitly when a result does not rule out carrier status, and why.

app.innovaregenetics.com
Pseudogene tab stating that a normal copy number does not rule out carrier status
Pseudogenes tab. Sample identifiers removed. Automated output, pending professional review and signature.

A negative covers only the loci in the table

Normal results are shown, because a negative also defines how far it reaches. Loci where the method cannot support a conclusion are listed separately, with the reason for each.

app.innovaregenetics.com
Repeat expansions tab listing loci with a reportable result and loci where no result can be stated
Repeat expansions tab. Sample identifiers removed. Automated output, pending professional review and signature.

What the screen does not cover, stated up front

Heterozygous variants in recessive and X-linked genes, with the reproductive-risk reading in plain language. Genes that need other methods, such as SMN1, FMR1 and HBA1/HBA2, are listed as not evaluated here.

app.innovaregenetics.com
Carrier screening tab with the genes the screen does not cover listed explicitly
Carriers tab. Sample identifiers removed. Automated output, pending professional review and signature.

Percentile, with the ancestry check beside it

Ancestry-adjusted percentiles per phenotype, and a flag where the inferred ancestry differs from the one the score was built on.

app.innovaregenetics.com
Polygenic risk table with ancestry-adjusted percentiles and an ancestry concordance flag per phenotype
Polygenic risk tab. Sample identifiers removed. Automated output, pending professional review and signature.
Worked example

Why CYP2D6 needs a specialised locus-specific analysis

The CYP2D7 pseudogene keeps very high sequence identity with CYP2D6. A short read in those blocks maps equally well to both, so the aligner assigns MAPQ 0 — and the caller drops it before interpretation begins.

22q13.2high-identity blocks shared with CYP2D7CYP2D8PCYP2D7CYP2D6A · Conventional germline pathsubstantial mapping ambiguityoutput: *1/*1 — false normalB · Specialised locus-specific analysiscoverage recoveredoutput: *2/*5 · CN=1 — structure resolvedread assignedMAPQ 0 — not usable for calling

In our measurement, a large fraction of the reads at this locus sit at MAPQ 0. Schematic representation; metrics measured on our own samples.

A specialised locus-specific analysis

Designed to improve interpretation in complex genomic regions, where a general-purpose path cannot support a reliable result.

Structure reported, not inferred

Whole-gene deletion and duplication are reported explicitly, with the copy number stated, instead of being left implicit in a variant list.

Phenotype, not a lookup table

CPIC and DPWG implications are tied to the metaboliser phenotype and the activity score that were actually inferred for that sample.

Coverage as governance

An independent step decides evaluability per gene before a report exists. It determines what can be asserted, and what cannot.

Read the full technical note

Three principles

What the architecture is actually optimised for

01

Make the analytical limits visible

Pseudogene regions, repeat expansions and copy-number events are exactly where a linear short-read pipeline can fail without saying so. Innovare records mapping quality and coverage per region and reports an unresolved region as unresolved, so a professional never has to guess whether a clean result was actually examined.

02

Make interpretation auditable

An engine that outputs only a verdict is a black box. Innovare records its full reasoning as a ledger, so the geneticist reviews how a classification was reached — not just what it was — and can adjust it before signing.

03

Calibrate for the real population

A polygenic score trained on one ancestry can mislead in another. Innovare infers ancestry explicitly and calibrates accordingly, with attention to the Iberian and admixed Latino populations our clients serve.

AI is used where it earns its place — prioritising findings and structuring interpretation — always in service of a professional who reviews the evidence and signs. It is assistance, not autonomy.

See the chain run on your data

Bring one representative case — ideally one where you suspect the answer was never actually computed.

app.innovaregenetics.com · for research laboratories, hospital research groups, pharma and research centres